Related Experiment Video
Updated: Jun 17, 2026
A Mouse Model for Laser-induced Choroidal Neovascularization
Published on: December 27, 2015
Anti-SPARC oligopeptide inhibits laser-induced CNV in mice
Hironori Uehara1, Ling Luo, Jacquelyn Simonis
1John A. Moran Eye Center, Department of Ophthalmology and Visual Sciences, University of Utah, 65 Mario Capecchi Dr., Salt Lake City, UT 84132, USA. Hironori.Uehara@hsc.utah.edu
Abstract:
It is known that SPARC gates VEGF-A signal transduction towards KDR, the primary angiogenic VEGF receptor. We sought to determine whether inhibition of SPARC activity using anti-SPARC peptide could inhibit laser-induced CNV by promoting binding of VEGF-A to FLT-1. We created anti-SPARC l-peptide and retro-inverso anti-SPARC d-peptide. Anti-SPARC peptides or PBS were injected intravitreally 1day before or after laser induction. Intravitreal injection of anti-SPARC l-peptide 1day before laser induction promotes FLT-1 phosphorylation and inhibited laser-induced CNV and anti-SPARC d-peptide had no effect. Injection 1day after laser injury did not affect size of laser-induced CNV. Inhibition of SPARC activity could be complementary to existing anti-CNV therapy.
Insights
Inhibiting SPARC with anti-SPARC peptide prevents choroidal neovascularization (CNV) by enhancing VEGF-A binding to FLT-1. This approach could complement current anti-CNV therapies.
Area of Science:
- Ophthalmology
- Molecular Biology
- Biochemistry
Background:
- SPARC (secreted protein acidic and rich in cysteine) modulates VEGF-A (Vascular Endothelial Growth Factor A) signaling.
- VEGF-A primarily signals through KDR (Kinase Insert Domain Receptor) to promote angiogenesis.
- Dysregulation of VEGF-A signaling is implicated in neovascular eye diseases like choroidal neovascularization (CNV).
Purpose of the Study:
- To investigate if inhibiting SPARC activity with an anti-SPARC peptide could suppress laser-induced CNV.
- To determine if SPARC inhibition promotes VEGF-A binding to FLT-1 (Fms-like tyrosine kinase 1), a known VEGF-A decoy receptor.
Main Methods:
- Development of anti-SPARC l-peptide and retro-inverso anti-SPARC d-peptide.
- Intravitreal injection of anti-SPARC peptides or phosphate-buffered saline (PBS) in a laser-induced CNV model.
- Assessment of FLT-1 phosphorylation and CNV size following peptide administration.
Main Results:
- Intravitreal administration of anti-SPARC l-peptide one day prior to laser induction promoted FLT-1 phosphorylation.
- Anti-SPARC l-peptide significantly inhibited laser-induced CNV formation.
- The retro-inverso d-peptide control and injections after laser injury did not show significant effects on CNV.
Conclusions:
- Inhibition of SPARC activity using anti-SPARC l-peptide can effectively reduce choroidal neovascularization.
- SPARC inhibition appears to redirect VEGF-A signaling towards FLT-1, thereby suppressing pathological angiogenesis.
- Targeting SPARC represents a potential adjunctive therapeutic strategy for managing CNV and related neovascular eye conditions.
